<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <atom:link rel="self" type="application/rss+xml" href="https://www.mynewsdesk.com/fi/rss/source/40/document"/>
    <title>AstraZeneca - tiedostot</title>
    <link>https://www.mynewsdesk.com/fi/astrazeneca/documents</link>
    <description>MyNewsdesk-syötteet suoraan lähteestä</description>
    <image>
      <title>AstraZeneca - tiedostot</title>
      <link>https://www.mynewsdesk.com/fi/astrazeneca/documents</link>
      <url>https://www.mynewsdesk.com/assets/graphics/logos/logo-small-3b24ab90.png</url>
      <width>128</width>
      <height>23</height>
    </image>
    <language>sv</language>
    <ttl>15</ttl>
<item>
  <title>Global facts on ovarian cancer </title>
  <pubDate>Mon, 07 May 2018 19:08:46 +0300</pubDate>
  <description></description>
  <guid>https://www.mynewsdesk.com/fi/astrazeneca/documents/global-facts-on-ovarian-cancer-78346?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=document</guid>
  <link>https://www.mynewsdesk.com/fi/astrazeneca/documents/global-facts-on-ovarian-cancer-78346?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=document</link>
  <dc:creator>AstraZeneca AB</dc:creator>
</item>
<item>
  <title>AstraZeneca, Zinforo - taustamateriaalia 2012</title>
  <pubDate>Wed, 12 Dec 2012 15:03:14 +0200</pubDate>
  <description></description>
  <guid>https://www.mynewsdesk.com/fi/astrazeneca/documents/astrazeneca-zinforo-taustamateriaalia-2012-23791?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=document</guid>
  <link>https://www.mynewsdesk.com/fi/astrazeneca/documents/astrazeneca-zinforo-taustamateriaalia-2012-23791?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=document</link>
  <dc:creator>AstraZeneca AB</dc:creator>
</item>
<item>
  <title>AZN-Q4_2011-Press Release</title>
  <pubDate>Wed, 08 Feb 2012 08:49:08 +0200</pubDate>
  <description></description>
  <guid>https://www.mynewsdesk.com/fi/astrazeneca/documents/azn-q4_2011-press-release-17962?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=document</guid>
  <link>https://www.mynewsdesk.com/fi/astrazeneca/documents/azn-q4_2011-press-release-17962?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=document</link>
  <dc:creator>AstraZeneca AB</dc:creator>
</item>
<item>
  <title>Tietoa keuhkosyövästä</title>
  <pubDate>Wed, 25 Jan 2012 13:55:08 +0200</pubDate>
  <description></description>
  <guid>https://www.mynewsdesk.com/fi/astrazeneca/documents/tietoa-keuhkosyoevaestae-17716?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=document</guid>
  <link>https://www.mynewsdesk.com/fi/astrazeneca/documents/tietoa-keuhkosyoevaestae-17716?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=document</link>
  <dc:creator>AstraZeneca AB</dc:creator>
</item>
<item>
  <title>Valmisteyhteenvetolyhennelmä Iressa</title>
  <pubDate>Wed, 25 Jan 2012 13:54:39 +0200</pubDate>
  <description></description>
  <guid>https://www.mynewsdesk.com/fi/astrazeneca/documents/valmisteyhteenvetolyhennelmae-iressa-16923?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=document</guid>
  <link>https://www.mynewsdesk.com/fi/astrazeneca/documents/valmisteyhteenvetolyhennelmae-iressa-16923?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=document</link>
  <dc:creator>AstraZeneca AB</dc:creator>
</item>
<item>
  <title>Gefitinibi taustatiedote</title>
  <pubDate>Wed, 25 Jan 2012 13:53:59 +0200</pubDate>
  <description></description>
  <guid>https://www.mynewsdesk.com/fi/astrazeneca/documents/gefitinibi-taustatiedote-17715?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=document</guid>
  <link>https://www.mynewsdesk.com/fi/astrazeneca/documents/gefitinibi-taustatiedote-17715?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=document</link>
  <dc:creator>AstraZeneca AB</dc:creator>
</item>
<item>
  <title>Briliquen valmisteyhteenvetolyhennelmä</title>
  <pubDate>Tue, 01 Nov 2011 13:06:28 +0200</pubDate>
  <description></description>
  <guid>https://www.mynewsdesk.com/fi/astrazeneca/documents/briliquen-valmisteyhteenvetolyhennelmae-16396?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=document</guid>
  <link>https://www.mynewsdesk.com/fi/astrazeneca/documents/briliquen-valmisteyhteenvetolyhennelmae-16396?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=document</link>
  <dc:creator>AstraZeneca AB</dc:creator>
</item>
<item>
  <title>Financial Summary QIII 2011</title>
  <pubDate>Mon, 31 Oct 2011 12:32:19 +0200</pubDate>
  <description>AstraZeneca Financial Summary QIII 2011</description>
  <guid>https://www.mynewsdesk.com/fi/astrazeneca/documents/financial-summary-qiii-2011-16368?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=document</guid>
  <link>https://www.mynewsdesk.com/fi/astrazeneca/documents/financial-summary-qiii-2011-16368?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=document</link>
  <dc:creator>AstraZeneca AB</dc:creator>
</item>
<item>
  <title>Zomig Nasal 5 mg valmisteyhteenveto</title>
  <pubDate>Thu, 27 Oct 2011 10:25:03 +0300</pubDate>
  <description></description>
  <guid>https://www.mynewsdesk.com/fi/astrazeneca/documents/zomig-nasal-5-mg-valmisteyhteenveto-16317?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=document</guid>
  <link>https://www.mynewsdesk.com/fi/astrazeneca/documents/zomig-nasal-5-mg-valmisteyhteenveto-16317?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=document</link>
  <dc:creator>AstraZeneca AB</dc:creator>
</item>
<item>
  <title>Valmisteyhteenveto Vimovo kipulääkkeelle</title>
  <pubDate>Fri, 21 Oct 2011 16:06:00 +0300</pubDate>
  <description>Tiedosto sisältää Vimovo kipulääkkeen valmisteyhteenvedon, jolle Lääkkeiden hintalautakunta on myöntänyt peruskorvattavuuden (42%) 1.7.2011 alkaen ohessa kuvatun käyttöaiheen mukaisesti.</description>
  <guid>https://www.mynewsdesk.com/fi/astrazeneca/documents/valmisteyhteenveto-vimovo-kipulaeaekkeelle-16179?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=document</guid>
  <link>https://www.mynewsdesk.com/fi/astrazeneca/documents/valmisteyhteenveto-vimovo-kipulaeaekkeelle-16179?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=document</link>
  <dc:creator>AstraZeneca AB</dc:creator>
</item>
  </channel>
</rss>
